According to the company, the rapid decline in plasma hepatitis C virus-RNA levels observed in patients taking VX-950, together with a viral kinetic analysis that projects the potential duration of treatment required to achieve sustained virologic response, support the evaluation of VX-950 in a novel, three-month combination treatment paradigm.
“The clinical data demonstrate a swift and dramatic decline in viral levels with VX-950, and provide insight into VX-950’s potential to transform future HCV treatment,” said Dr Joshua Boger, CEO of Vertex.
Vertex has now filed an investigational new drug application with the FDA to support phase II clinical development of the drug.